FIGURE 4.
FIGURE 4.
Survival analysis of B16/F1 murine melanoma-bearing C57 mice. Kaplan–Meier survival curves for B16/F1 murine melanoma-bearing mice treated with 7.4 MBq (▾), 22.2 MBq (▴), and 2 × 14.8 MBq (▪) of 188Re-(Arg11)CCMSH or saline placebo (□). Mean survival time was 9.4 ± 1.1 d for untreated control group, 10.2 ± 1.0 d (P > 0.05) for group treated with 7.4 MBq, 10.3 ± 1.3 d (P > 0.05) for group treated with 22.2 MBq, and 13.3 ± 1.9 d (P < 0.05) for group treated with 2 × 14.8 MBq.
In this issue
Related Articles
Cited By...
- A tumor-targeted immune checkpoint blocker
- Effects of the Amino Acid Linkers on the Melanoma-Targeting and Pharmacokinetic Properties of 111In-Labeled Lactam Bridge-Cyclized {alpha}-MSH Peptides
- Preclinical Evaluation of an 131I-Labeled Benzamide for Targeted Radiotherapy of Metastatic Melanoma
- Reduction of the Ring Size of Radiolabeled Lactam Bridge-Cyclized {alpha}-MSH Peptide, Resulting in Enhanced Melanoma Uptake
- 203Pb-Labeled {alpha}-Melanocyte-Stimulating Hormone Peptide as an Imaging Probe for Melanoma Detection
- Small-Animal PET of Melanocortin 1 Receptor Expression Using a 18F-Labeled {alpha}-Melanocyte-Stimulating Hormone Analog
- 99mTc- and 111In-Labeled {alpha}-Melanocyte-Stimulating Hormone Peptides as Imaging Probes for Primary and Pulmonary Metastatic Melanoma Detection
- Melanoma Therapy via Peptide-Targeted {alpha}-Radiation